FrancophonIA/ELRC3.0 huggingface dataset:
English: On days that Empliciti is administered, patients ≤ 75 years old give dexamethasone 28 mg orally between 3 and 24 hours before Empliciti plus 8 mg intravenously between 45 and 90 minutes before Empliciti and for patients > 75 years old give dexamethasone 8 mg orally between 3 and 24 hours before Empliciti plus 8 mg intravenously between 45 and 90 minutes before Empliciti.
Danish: På dage, hvor Empliciti administreres, til patienter ≤ 75 år gives dexamethason 28 mg oralt mellem 3 og 24 timer før Empliciti plus 8 mg intravenøst mellem 45 og 90 minutter før Empliciti og til patienter > 75 år gives dexamethason 8 mg oralt mellem 3 og 24 timer før Empliciti plus 8 mg intravenøst mellem 45 og 90 minutter før Empliciti.
English: You should not be given Empliciti: if you are allergic to elotuzumab or any of the other ingredients of this medicine (listed in section 6 “Contents of the pack and other information”).
Danish: Det skal du vide, før du begynder at bruge Empliciti Brug ikke Empliciti: hvis du er allergisk over for elotuzumab eller et af de øvrige indholdsstoffer i Empliciti (angivet i afsnit 6).
English: Very Good Partial Response (VGPR) n (%) Partial Response (RR/PR) n (%) Combined Responses (CR+sCR+VGPR) n (%) 12 (20.0)
Danish: Meget god delvis respons (VGPR) n (%) Delvis respons (RR/PR) n (%) Kombineret respons (CR+sCR+VGPR) n (%)
English: Elotuzumab 10 mg/kg was administered intravenously each week for the first 2 cycles and every 2 weeks thereafter.
Danish: Elotuzumab 10 mg/kg blev administreret intravenøst hver uge i de første 2 cyklusser og derefter hver anden uge.
English: The recommended dose of Empliciti is 10 mg/kg administered intravenously every week on days 1, 8, 15, and 22 of each treatment cycle for the first two cycles and then 20 mg/kg administered on day 1 of each treatment cycle thereafter.
Danish: Den anbefalede dosis Empliciti er 10 mg/kg administreret intravenøst hver uge på dag 1, 8, 15 og 22 i hver behandlingscyklus i de første to cyklusser og derefter 20 mg/kg administreret på dag 1 i hver behandlingscyklus.
English: The recommended dose of Empliciti is 10 mg/kg administered intravenously every week, on days 1, 8, 15, and 22 for the first two treatment cycles and every 2 weeks thereafter on days 1 and 15.
Danish: Den anbefalede dosis Empliciti er 10 mg/kg administreret intravenøst hver uge på dag 1, 8, 15 og 22 i de første to behandlingscyklusser og derefter hver anden uge på dag 1 og 15.
English: a p-value based on the log-rank test stratified by stage of disease at study entry (International Staging System I-II vs III) and number of prior lines of therapy (2-3 vs ≥ 4) at randomization.
Danish: a p-værdi baseret på log-rank test stratificeret efter sygdomsstadie ved indtrædelse i studiet (International Staging System I-II versus III) og antal tidligere behandlingslinjer (2-3 versus ≥ 4) ved randomisering.
English: HR (95.4% CI): 0.82 (0.68, 1.00) p-value: 0.0408
Danish: HR (95,4% CI): 0,82 (0,68; 1,00) p-værdi: 0,0408
English: Mood changes
Danish: Humørsvingninger
English: Aseptically reconstitute each Empliciti vial with a syringe of adequate size and an 18 gauge or smaller needle as shown in Table 1.
Danish: Hvert Empliciti-hætteglas rekonstitueres aseptisk med en sprøjte af passende størrelse og en 18 gauge kanyle eller mindre som vist i tabel 1.
English: The median age was 66 years (range 37 to 91); 57% of patients were older than 65 years; 60% of patients were male; Whites comprised 84% of the study population, Asians 10%, and blacks 4%.
Danish: Medianalderen var 66 år (interval 37 til 91); 57% af patienterne var ældre end 65 år; 60% af patienterne var mænd.
English: c p-value based on the Cochran-Mantel-Haenszel chi-square test stratified by stage of disease at study entry (International Staging System I-II vs III) and number of prior lines of therapy (2-3 vs ≥ 4) at randomization.
Danish: c p-værdi baseret på Cochran-Mantel-Haenszel chi-i‑anden‑test stratificeret efter sygdomsstadie ved indtrædelse i studiet (International Staging System I-II versus III) og antal tidligere behandlingslinjer (2-3 versuss ≥ 4) ved randomisering.
English: The total elotuzumab dose in mg equals the patient's weight in kg multiplied by the elotuzumab dose (10 or 20 mg/kg, see section 4.2).
Danish: Total elotuzumab-dosis i mg svarer til patientens vægt i kg multipliceret med elotuzumab-dosis (10 eller 20 mg/kg, se pkt.
English: Elotuzumab will be given in combination with lenalidomide or pomalidomide and breast-feeding should be stopped because of the use of lenalidomide or pomalidomide.
Danish: Elotuzumab gives sammen med lenalidomid eller pomalidomid, og som følge af anvendelsen af lenalidomid eller pomalidomid skal amningen ophøre.
English: b The term pneumonia is a grouping of the following terms: pneumonia, atypical pneumonia, bronchopneumonia, lobar pneumonia, bacterial pneumonia, fungal pneumonia, pneumonia influenza, and pneumococcal pneumonia.
Danish: Pneumoni er en sammensat term, der omfatter følgende termer: pneumoni, atypisk pneumoni, bronkopneumoni, lobær pneumoni, bakteriel pneumoni, fungal pneumoni, influenzapneumoni og pneumokokpneumoni.
English: No dose adjustment for Empliciti is required for patients with mild hepatic impairment (total bilirubin [TB] ≤ to the upper limit of normal [ULN] and AST > ULN or TB < 1 to 1.5 × ULN and any AST).
Danish: Dosisjustering af Empliciti er ikke nødvendig hos patienter med let nedsat leverfunktion (total-bilirubin [TB] ≤ øvre normalgrænse [ULN] og ASAT > ULN eller TB < 1-1,5 x ULN og enhver ASAT).
English: Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).
Danish: Empliciti er i kombination med lenalidomid og dexamethason indiceret til behandling af myelomatose hos voksne patienter, som har fået mindst en tidligere behandling (se pkt.
English: Empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy (see sections 4.2 and 5.1).
Danish: Empliciti er i kombination med pomalidomid og dexamethason indiceret til behandling af voksne patienter med relaps og refraktær myelomatose, som tidligere har fået mindst to behandlinger herunder lenalidomid og en proteasomhæmmer, og som har vist sygdomsprogression under den sidste behandling (se pkt.
English: The median age was 67 years (range 36 to 81); 62% of patients were older than 65 years; 57% of patients were male; whites comprised 77% of the study population, Asians 21%, and blacks 1%.
Danish: Medianalderen var 67 år (interval 36 til 81); 62% af patienterne var ældre end 65 år; 57% af patienterne var mænd.
English: a p-value based on the log-rank test stratified by B2 microglobulins (<3.5 mg/L versus ≥ 3.5 mg/L), number of prior lines of therapy (1 versus 2 or 3), and prior immunomodulatory therapy (no versus prior thalidomide only versus other).
Danish: a p-værdi baseret på log-rank test stratificeret efter B2 mikroglobuliner (<3,5 mg/l versus ≥ 3,5 mg/l), antal tidligere behandlinger (1 versus 2 eller 3) og tidligere immunmodulerende behandling (ingen versus tidligere udelukkende thalidomid versus anden behandling).
English: In a clinical trial of patients with multiple myeloma (CA204125), infections were reported in 65% of patients in the Empliciti combined with pomalidomide and dexamethasone arm (N = 60) and 65.5% in the pomalidomide and dexamethasone arm (N = 55).
Danish: I et klinisk forsøg med patienter med myelomatose (CA204125) blev infektioner rapporteret hos 65% af patienterne i armen med Empliciti kombineret med pomalidomid og dexamethason (N = 60) og hos 65,5% i armen med pomalidomid og dexamethason (N = 55).
English: Empliciti + Pomalidomide and Dexamethasone N = 60
Danish: Empliciti + Pomalidomid og dexamethason N = 60
English: Pomalidomide and Dexamethasone N = 55
Danish: Pomalidomid og dexamethason N = 55
English: Elotuzumab 10 mg/kg was administered intravenously each week for the first 2 cycles and 20 mg/kg every 4 weeks thereafter.
Danish: Elotuzumab 10 mg/kg blev administreret intravenøst hver uge i de første 2 cyklusser og derefter 20 mg/kg hver 4. uge.
English: Lenalidomide and Dexamethasone N = 317
Danish: Lenalidomid og dexamethason N = 317
English: EU/1/16/1088/001-002
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/16/1088/001-002
English: The administration of the reconstituted and diluted solution must be initiated at an infusion rate of 0.5 mL/min.
Danish: Administration af den rekonstituerede og fortyndede infusionsvæske skal initieres ved en infusionshastighed på 0,5 ml/min.
English: Table 7: CA204125 Exposure-adjusted rates for adverse reactions for Empliciti-treated patients versus pomalidomide and dexamethasone-treated patients [includes multiple occurrences in all treated patients]
Danish: Tabel 7: CA204125 Hyppighed af bivirkninger, justeret i forhold til eksponering, hos patienter behandlet med Empliciti versus patienter behandlet med pomalidomid og dexamethason [inkluderer flere forekomster hos alle behandlede patienter]
English: Table 1: Recommended dosing schedule of Empliciti in combination with lenalidomide and dexamethasone
Danish: Tabel 1: Anbefalet doseringsskema for Empliciti i kombination med lenalidomid og dexamethason
English: CA204125 is a randomised, open-label study conducted to evaluate the efficacy and safety of Empliciti in combination with pomalidomide and dexamethasone (E-Pd) in patients with refractory or relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and had disease progression on or within 60 days of their last therapy.
Danish: Empliciti i kombination med pomalidomid og dexamethason (CA204125) CA204125 er et randomiseret, åbent studie, der blev udført for at undersøge Emplicitis virkning og sikkerhed i kombination med pomalidomid og dexamethason (E-Pd) hos patienter med refraktær eller relaps og refraktær myelomatose, som har fået mindst to tidligere behandlinger inklusive lenalidomid og en proteasomhæmmer (PI), og havde sygdomsprogression indenfor 60 dage før, eller på, den sidste behandlingsdag.
English: When Empliciti is used with lenalidomide or pomalidomide there is a risk of foetal harm, including severe life-threatening human birth defects associated with these agents and the need to follow requirements regarding pregnancy avoidance, including testing and contraception.
Danish: Når Empliciti anvendes sammen med lenalidomid eller pomalidomid, er der en risiko for fosterskader, inklusive livstruende medfødte misdannelser, forbundet med disse præparater.
English: Sore throat
Danish: Ondt i halsen
English: Empliciti at 10 mg/kg dose should be initiated at an infusion rate of 0.5 mL/min.
Danish: Ved en dosis på 10 mg/kg skal Empliciti initieres med en infusionshastighed på 0,5 ml/min.
English: Empliciti at 20 mg/kg dose should be initiated at an infusion rate of 3 mL/min.
Danish: Ved en dosis på 20 mg/kg skal Empliciti initieres med en infusionshastighed på 3 ml/min.
English: The incidence of infections, including pneumonia, was higher with Empliciti treatment than with control (see section 4.4).
Danish: Infektioner, inklusive pneumoni, forekom hyppigere i Empliciti-armen end i kontrolarmen (se pkt.
English: Table 6: CA204004 Exposure-adjusted rates for adverse reactions for Empliciti-treated patients versus lenalidomide and dexamethasone-treated patients [includes multiple occurrences in all treated patients]
Danish: Tabel 6: CA204004 Hyppighed af bivirkninger, justeret i forhold til eksponering hos patienter behandlet med Empliciti versus patienter behandlet med lenalidomid og dexamethason [inkluderer flere forekomster hos alle behandlede patienter]
English: The administration of reconstituted and diluted solution must be initiated at an infusion rate of 3 mL/min.
Danish: Administration af den rekonstituerede og fortyndede infusionsvæske skal initieres ved en infusionshastighed på 3 ml/min.
English: Prior therapies included stem cell transplant (55%), bortezomib (100%), lenalidomide (99%), cyclophosphamide (66%), melphalan (63%), carfilzomib (21%), ixazomib (6%), and daratumumab (3%).
Danish: Syvogfirs procent (87%) af de patienter var refraktære over for lenalidomid, 80% refraktære over for en PI og 70% var refraktære over for både lenalidomid og en PI. Tidligere behandlinger inkluderede stamcelletransplantation (55%), bortezomib (100%), lenalidomid (99%), cyclophosphamid (66%), melphalan (63%), carfilzomib (21%), ixazomib (6%), og daratumumab (3%).
English: d p-value based on the Cochran-Mantel-Haenszel chi-square test stratified by B2 microglobulins (<3.5 mg/L versus ≥ 3.5 mg/L), number of prior lines of therapy (1 versus 2 or 3), and prior immunomodulatory therapy (no versus prior thalidomide only versus other).
Danish: d p-værdi baseret på Cochran-Mantel-Haenszel chi i-anden-test- stratificeret efter B2-mikroglobuliner (<3,5 mg/l versus ≥ 3,5 mg/l), antal tidligere behandlinger (1 versus 2 eller 3) og tidligere immunmodulerende behandling (ingen versus tidligere udelukkende thalidomid versus anden behandling).
English: Grade 3-4 infections were noted in 13.3% and 21.8% of Empliciti combined with pomalidomide and dexamethasone and pomalidomide and dexamethasone treated patients, respectively.
Danish: Grad 3-4 infektioner blev observeret hos 13,3% og 21,8% af patienterne, som blev behandlet med henholdsvis Empliciti kombineret med pomalidomid og dexamethason og pomalidomid kombineret med dexamethason.
English: SPMs are known to be associated with lenalidomide exposure, which was extended in patients treated with Empliciti combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone.
Danish: SPM er kendt for at være associeret med lenalidomideksponering, hvilket også gjaldt for patienter, der blev behandlet med Empliciti kombineret med lenalidomid og dexamethason versus lenalidomid og dexamethason.
English: a The term cough includes the following terms: cough, productive cough, and upper airway cough syndrome.
Danish: a Termen hoste omfatter følgende termer: hoste, produktiv hoste og øvre luftvej-hoste-syndrom.
English: If you have any further questions, ask your doctor, or pharmacist or nurse.
Danish: Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er mere, du vil vide.
English: How to use Empliciti
Danish: Sådan skal du bruge Empliciti
English: You must use effective contraception while you are being treated with Empliciti, if there is any chance you could become pregnant.
Danish: Hvis der er en chance for, at du kan blive gravid, skal du anvende sikker prævention, mens du er i behandling med Empliciti.
English: Empliciti + Lenalidomide and Dexamethasone N = 318
Danish: Empliciti + lenalidomid og dexamethason N = 318
English: Lymphopeniac
Danish: Lymfopenib
English: Exposure-adjusted rates for adverse reactions (all Grades and Grade 3/4) in CA204125, a clinical trial in patients with multiple myeloma comparing Empliciti combined with pomalidomide and dexamethasone treatment (N = 60) to pomalidomide and dexamethasone treatment (N = 55), is shown in Table 7.
Danish: Hyppigheden af bivirkninger (alle grader og grad 3/4), justeret i forhold til eksponering, i CA204125, et klinisk forsøg med patienter med myelomatose, som sammenlignede behandling med Empliciti kombineret med pomalidomid og dexamethason (N = 60) med pomalidomid og dexamethason (N = 55), er vist i tabel 7.
English: d The term herpes zoster is a grouping of the following terms: herpes zoster, oral herpes, herpes virus infection and ophthalmic herpes zoster.
Danish: d Herpes zoster er en sammensat term, der omfatter følgende termer: herpes zoster, oral herpes, herpes virusinfektion, og oftalmisk herpes zoster.
English: Anti-product antibodies resolved by 2 to 3 months in 18 (95%) of these 19 patients.
Danish: Hos 18 (95%) ud af 19 patienter forsvandt antistofferne mod lægemidlet efter 2 til 3 måneder.
English: Fatal infections were infrequent and were reported in 2.5% of Empliciti combined with lenalidomide and dexamethasone and 2.2% of lenalidomide and dexamethasone treated patients.
Danish: Dødelige infektioner var ikke hyppige og blev rapporteret hos 2,5% af patienterne i armen med Empliciti kombineret med lenalidomid og dexamethason og hos 2,2% i armen med lenalidomid og dexamethason.
English: b The term lymphopenia includes the following terms: lymphopenia and lymphocyte count decreased.
Danish: b Termen lymfopeni omfatter følgende termer: lymfopeni og nedsat lymfocyttal.
English: Uncommon a The term herpes zoster is a grouping of the following terms: herpes zoster, oral herpes, and herpes virus infection.
Danish: Ikke almindelig a Herpes zoster er en sammensat term, der omfatter følgende termer: herpes zoster, oral herpes og herpes virusinfektion.
English: Fatal infections (i.e. Grade 5 infections) were reported in 5% of Empliciti combined with pomalidomide and dexamethasone and 3.6% of pomalidomide and dexamethasone treated patients.
Danish: Grad 5 infektioner) blev rapporteret hos 5% af patienterne i armen med Empliciti kombineret med pomalidomid og dexamethason og hos 3,6% i armen med pomalidome og dexamethason.
English: IV use.
Danish: anvendelse.
English: Empliciti is available in packs containing 1 vial.
Danish: Empliciti fås i pakninger med 1 hætteglas.
English: Second Primary Malignancies are known to be associated with lenalidomide exposure which was extended in patients treated with Empliciti combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone.
Danish: Andre primære maligniteter er kendt for at være associeret med lenalidomideksponering, hvilket også gjaldt for patienter, der blev behandlet med Empliciti kombineret med lenalidomid og dexamethason versus lenalidomid og dexamethason.
English: In the clinical trials of patients with multiple myeloma infusion reactions were reported in approximately 10% of premedicated patients treated with Empliciti combined with lenalidomide and dexamethasone (N = 318) and 3% of premedicated patients treated with Empliciti combined with pomalidomide and dexamethasone (N = 60) (see section 4.4).
Danish: I de kliniske forsøg med patienter med myelomatose blev infusionsreaktioner rapporteret hos ca. 10% af de præmedicinerede patienter, der blev behandlet med Empliciti kombineret med lenalidomid og dexamethason (N = 318) og 3% af de præmedicinerede patienter behandlet med Empliciti kombineret med pomalidomid og dexamthason (N = 60) (se pkt.
English: Grade 3-4 infections were noted in 28% and 24.3% of Empliciti combined with lenalidomide and dexamethasone and lenalidomide and dexamethasone treated patients, respectively.
Danish: Grad 3-4 infektioner blev observeret hos 28% og 24,3% af patienterne, som blev behandlet med henholdsvis Empliciti kombineret med lenalidomid og dexamethason og lenalidomid kombineret med dexamethason.
English: c The term lymphopenia includes the following terms: lymphopenia and lymphocyte count decreased.
Danish: c Termen lymfopeni omfatter følgende termer: lymfopeni og nedsat lymfocyttal.
English: d The term cough includes the following terms: cough, productive cough, and upper airway cough syndrome.
Danish: d Termen hoste omfatter følgende termer: hoste, produktiv hoste og øvre luftvej-hoste-syndrom.
English: Among, patients treated with aspirin, deep vein thromboses were reported in 4.1% of patients treated with Empliciti combined with lenalidomide and dexamethasone (E-Ld) and 1.4% of patients treated with lenalidomide and dexamethasone (Ld).
Danish: Blandt de patienter, der blev behandlet med acetylsalisylsyre, blev dyb venetrombose rapporteret hos 4,1% af patienterne i armen med Empliciti kombineret med lenalidomid og dexamethason (E-Ld) og hos 1,4% i armen med lenalidomid og dexamethason (Ld).
English: E-Ld 321 282 240 206 164 133 87 43 12 1
Danish: E-Ld 321 282 240 206 164 133 87 43 12 1 Ld 325 262 204 168 130 97 53 24 7
English: Do not store any unused portion of the infusion solution for reuse.
Danish: Eventuelt resterende infusionsvæske må ikke opbevares til senere brug.
English: The high risk cytogenetic categories of del17p and t(4;14) were present in 32% and 9% of patients, respectively.
Danish: Henholdsvis 32% og 9% af patienterne havde høj cytogenetisk risiko i form af del17p og t(4;14).
English: Empliciti, as a humanised monoclonal antibody, is not expected to be metabolised by cytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or induction of these enzymes by co-administered medicinal products is not anticipated to affect the pharmacokinetics of Empliciti.
Danish: Elotozumab, som er et humaniseret monoklonalt antistof, forventes ikke at blive metaboliseret af CYP-enzymer eller andre lægemiddelmetaboliserende enzymer.
English: Infusion rate for Empliciti 10 mg/kg
Danish: Infusionshastighed for Empliciti 10 mg/kg
English: Infusion rate for Empliciti 20 mg/kg
Danish: Infusionshastighed for Empliciti 20 mg/kg
English: Exposure-adjusted rates for adverse reactions (all Grades and Grade 3/4) in CA204004, a clinical trial in patients with multiple myeloma comparing Empliciti combined with lenalidomide and dexamethasone treatment (N = 318) to lenalidomide and dexamethasone treatment (N = 317), is shown in Table 6.
Danish: Hyppigheden af bivirkninger (alle grader og grad 3/4), justeret i forhold til eksponering, i CA204004, et klinisk forsøg med patienter med myelomatose, som sammenlignede Empliciti kombineret med lenalidomid og dexamethason (N = 318) med lenalidomid og dexamethason (N = 317), er vist i tabel 6.
English: CA204004 is a randomised, open-label study was conducted to evaluate the efficacy and safety of Empliciti in combination with lenalidomide and dexamethasone (E-Ld) in patients with multiple myeloma who have received one to three prior therapies.
Danish: Empliciti i kombinaiton med lenalidomid og dexamethason (CA204004) CA204004 er et randomiseret, åbent studie, der blev udført for at undersøge Emplicitis virkning og sikkerhed i kombination med lenalidomid og dexamethason (E-Ld) hos patienter med myelomatose, som har fået en til tre tidligere behandlinger.
English: Empliciti 400 mg powder for concentrate for solution for infusion Each vial contains 400 mg elotuzumab.
Danish: Empliciti 400 mg pulver til koncentrat til infusionsvæske, opløsning Et hætteglas indeholder 400 mg elotuzumab.
English: Very Good Partial Response (VGPR) n (%) Partial Response (RR/PR) n (%) Combined Responses (CR+sCR+VGPR) n (%) Overall Survivalg Hazard Ratio [95.4% CI] Stratified log-rank test p-value
Danish: Meget god delvis respons (VGPR) n (%) Delvis respons (RR/PR) n (%) Kombineret respons (CR+sCR+VGPR) n (%) Samlet overlevelse (OS)g
English: 0 - 30 min 0.5 mL/min 0 - 30 min 3 mL/min
Danish: 0 - 30 min 0,5 ml/min
English: Empliciti 300 mg powder for concentrate for solution for infusion Empliciti 400 mg powder for concentrate for solution for infusion elotuzumab
Danish: Empliciti 300 mg pulver til koncentrat til infusionsvæske, opløsning Empliciti 400 mg pulver til koncentrat til infusionsvæske, opløsning elotuzumab
English: In a clinical trial of patients with multiple myeloma that compared Empliciti combined with lenalidomide and dexamethasone treatment to lenalidomide and dexamethasone treatment (CA204004), the incidence of SPMs, and specifically of solid tumours and non-melanoma skin cancer, was higher in patient treated with Empliciti (see section 4.8).
Danish: Andre primære maligniteter (second primary malignancies - SPMer) I et klinisk forsøg, som sammenlignede behandling med Empliciti kombineret med lenalidomid og dexamethason og behandling med lenalidomid og dexamethason (CA204004) hos patienter med myelomatose, forekom SPMer og især solide tumorer og ikke-melanom hudcancer hyppigere hos patienter i Empliciti-armen (se pkt.